BioXcel Therapeutics, Inc. — Form 8-K
Filed September 1, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
BioXcel Therapeutics filed an 8-K on 2026-09-01 disclosing Item 2.03 (creation of direct financial obligation) and Item 3.01 (delisting notice or listing standards failure). No specific dollar amounts, counterparties, dates, or terms are disclosed in the header metadata. The filing indicates potential exchange delisting and a new financial obligation, but concrete details are absent from available text.
Why this rating
Delisting and new debt are existential threats to an $11M company; either alone is business-changing; combined suggests severe distress.
Extracted items
- 2.03 material obligation
- 3.01 delisting notice
Price action (we called it negative)
before filing · preread $0.16 ▼ 1.97% | at our read · unknown $0.16 | +10 min · unknown $0.16 ▲ 0.00% | +30 min · unknown $0.16 ▲ 0.00% | +1 hr pending | +4 hrs pending |
The stock had already moved +2.01% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.